Whole-genome sequencing of paired tumor and blood samples from 65 bladder cancer patients

65 paired tumor and normal whole-genome sequencing samples from urothelial bladder carcinomas (UBC, the most common type of bladder cancer) are used to uncover the whole-genome mutational landscape of UBC. Recurrent mutations in noncoding regions affecting gene regulatory elements and structural variations leading to gene disruptions are prevalent in this type of cancer.

65 samples
DAC: EGAC00001001098

Access Policy1 Study Files

Metadata

Request Access

The TAHSU BC policy

Following the policy of EGA and the listed TAHSU DAC policy. 1. Recipient shall use the Data solely for scientific studies and for no other purpose, including without limitation any commercial purpose or research. 2. Recipient agrees that there will be no attempts made to use the Data for the purpose of uniquely identifying a natural person. 3. Recipient shall not sell, transfer, disclose or otherwise provide access to the Data without the written consent of the Provider. 4. Nothing in this Agreement shall be construed as conferring on Recipient any express or implied license or option to license the Data, or any intellectual property owned or controlled by the Provider.

Studies are experimental investigations of a particular phenomenon, e.g., case-control studies on a particular trait or cancer research projects reporting matching cancer normal genomes from patients.

Study ID	Study Title	Study Type
EGAS00001003388	Whole-genome sequencing identifies ADGRG6 enhancer mutations and FRS2 duplications as angiogenesis-related drivers in bladder cancer	Other

This table displays only public information pertaining to the files in the dataset. If you wish to access this dataset, please submit a request. If you already have access to these data files, please consult the download documentation.

ID	File Type	Size	Located in
EGAF00002293602	vcf	867.9 MB
1 File (867.9 MB)